Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379796458> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4379796458 endingPage "e95" @default.
- W4379796458 startingPage "e95" @default.
- W4379796458 abstract "Objective: Background Telmisartan have potent blood pressure lowering effect as well as the other pleiotrophic effects including PPAR-??/?? dual activation. In large clinical studies, telmisartan demonstrated the comparable clinical benefits with angiotensin converting enzyme inhibitor. However, there were few studies of direct comparison between telmisartan and the other angiotensin receptor blockers (ARBs). This study aimed to compare the cardiovascular and renal protective effect between telmisartan and the other ARBs in patients with the advanced hypertension who required two or more anti-hypertensive drugs. Design and method: This study used the Observation Medical Outcomes Partnership-Common Data Model database of three tertiary hospitals in Korea. 19,247 Patients were prescribed at least two antihypertensive drugs including ARBs, were selected from January 1, 2017 to December 31, 2019. 3,437 patients in the telmisartan group and 15,810 patients in the other ARB group were matched 1:1 through propensity score matching. Major adverse cardiovascular event (MACE), heart failure (HF) hospitalization and new-onset dialysis were compared for 3,386 patients in each group. Result: Before the matching, there was a higher proportion of patients with a history of myocardial infarction (MI) in the telmisartan group compared to the other ARB group. After the matching, average on-treatment blood pressure was similar between two groups. Over a three-year period, the incidence of MACE and HF hospitalization did not differ significantly between the two groups. Compared to the other ARB group, the telmisartan group had a lower incidence of new-onset dialysis (1.3% vs 1.9%, p-value = 0.04). However, this difference was not statistically significant in the multivariable Cox regression model. Conclusions: Telmisartan has similar cardiovascular and renal protective effects to other ARBs in patients with advanced hypertension who are taking at least two anti-hypertensive medications. Figure. Kaplan-Meier curves showing the incidence of MACE and dialysis in the telmisartan group and the other ARB group." @default.
- W4379796458 created "2023-06-09" @default.
- W4379796458 creator A5032246382 @default.
- W4379796458 creator A5037704369 @default.
- W4379796458 creator A5040837657 @default.
- W4379796458 creator A5088784469 @default.
- W4379796458 date "2023-06-01" @default.
- W4379796458 modified "2023-09-23" @default.
- W4379796458 title "COMPARISON OF CLINICAL BENEFITS BETWEEN TELMISARTAN AND OTHER ANGIOTENSIN RECEPTOR BLOCKERS IN HYPERTENSION PATIENTS WITH COMBINATION THERAPY: MULTICENTER REAL-WORLD STUDY" @default.
- W4379796458 doi "https://doi.org/10.1097/01.hjh.0000939672.01984.3c" @default.
- W4379796458 hasPublicationYear "2023" @default.
- W4379796458 type Work @default.
- W4379796458 citedByCount "0" @default.
- W4379796458 crossrefType "journal-article" @default.
- W4379796458 hasAuthorship W4379796458A5032246382 @default.
- W4379796458 hasAuthorship W4379796458A5037704369 @default.
- W4379796458 hasAuthorship W4379796458A5040837657 @default.
- W4379796458 hasAuthorship W4379796458A5088784469 @default.
- W4379796458 hasBestOaLocation W43797964581 @default.
- W4379796458 hasConcept C120665830 @default.
- W4379796458 hasConcept C121332964 @default.
- W4379796458 hasConcept C126322002 @default.
- W4379796458 hasConcept C164705383 @default.
- W4379796458 hasConcept C2778198053 @default.
- W4379796458 hasConcept C2779716603 @default.
- W4379796458 hasConcept C2780400711 @default.
- W4379796458 hasConcept C2780739214 @default.
- W4379796458 hasConcept C500558357 @default.
- W4379796458 hasConcept C61511704 @default.
- W4379796458 hasConcept C71924100 @default.
- W4379796458 hasConcept C84393581 @default.
- W4379796458 hasConceptScore W4379796458C120665830 @default.
- W4379796458 hasConceptScore W4379796458C121332964 @default.
- W4379796458 hasConceptScore W4379796458C126322002 @default.
- W4379796458 hasConceptScore W4379796458C164705383 @default.
- W4379796458 hasConceptScore W4379796458C2778198053 @default.
- W4379796458 hasConceptScore W4379796458C2779716603 @default.
- W4379796458 hasConceptScore W4379796458C2780400711 @default.
- W4379796458 hasConceptScore W4379796458C2780739214 @default.
- W4379796458 hasConceptScore W4379796458C500558357 @default.
- W4379796458 hasConceptScore W4379796458C61511704 @default.
- W4379796458 hasConceptScore W4379796458C71924100 @default.
- W4379796458 hasConceptScore W4379796458C84393581 @default.
- W4379796458 hasIssue "Suppl 3" @default.
- W4379796458 hasLocation W43797964581 @default.
- W4379796458 hasOpenAccess W4379796458 @default.
- W4379796458 hasPrimaryLocation W43797964581 @default.
- W4379796458 hasRelatedWork W1871392962 @default.
- W4379796458 hasRelatedWork W2020050573 @default.
- W4379796458 hasRelatedWork W2049397185 @default.
- W4379796458 hasRelatedWork W2089715561 @default.
- W4379796458 hasRelatedWork W2110653948 @default.
- W4379796458 hasRelatedWork W2356526470 @default.
- W4379796458 hasRelatedWork W2399063111 @default.
- W4379796458 hasRelatedWork W2943471851 @default.
- W4379796458 hasRelatedWork W2969704120 @default.
- W4379796458 hasRelatedWork W4304166097 @default.
- W4379796458 hasVolume "41" @default.
- W4379796458 isParatext "false" @default.
- W4379796458 isRetracted "false" @default.
- W4379796458 workType "article" @default.